Mathur R, Alver BH, San Roman AK, Wilson BG, Wang X, Agoston AT, Park PJ, Shivdasani RA, Roberts CW. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nat Genet. 2017;49(2):296–302.

Article  PubMed  CAS  Google Scholar 

Mittal P, Roberts CW. The SWI/SNF complex in cancer—biology, biomarkers and therapy. Nat Rev Clin Oncol. 2020;17(7):435–48.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu R-C, Wang T-L, Shih I-M. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther. 2014;15(6):655–64.

Article  PubMed  PubMed Central  Google Scholar 

Xu S, Sak A, Niedermaier B, Erol YB, Groneberg M, Mladenov E, Kang M, Iliakis G, Stuschke M. Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy. Front Oncol. 2022;12: 999626.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang J, Yan H-B, Zhang Q, Liu W-Y, Jiang Y-H, Peng G, Wu F-Z, Liu X, Yang P-Y, Liu F. Enhancement of E-cadherin expression and processing and driving of cancer cell metastasis by ARID1A deficiency. Oncogene. 2021;40(36):5468–81.

Article  PubMed  CAS  Google Scholar 

Mandal J, Mandal P, Wang T-L, Shih I-M. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. J Biomed Sci. 2022;29(1):71.

Article  PubMed  PubMed Central  CAS  Google Scholar 

O’Neil NJ, Bailey ML, Hieter P. Synthetic lethality and cancer. Nat Rev Genet. 2017;18(10):613–23.

Article  PubMed  CAS  Google Scholar 

Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle. 2009;8(19):3112–9.

Article  PubMed  CAS  Google Scholar 

Zhao S, Wu W, Jiang Z, Tang F, Ding L, Xu W, Ruan L. Roles of ARID1A variations in colorectal cancer: a collaborative review. Mol Med. 2022;28(1):42.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu C, Lyu J, Yang EJ, Liu Y, Zhang B, Shim JS. Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells. Nat Commun. 2018;9(1):3212.

Article  PubMed  PubMed Central  Google Scholar 

Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W. Aurora kinase inhibitors-rising stars in cancer therapeutics? Mol Cancer Ther. 2010;9(2):268–78.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S. Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer: a randomized clinical trial. JAMA Oncol. 2019;5(1):e183773–e183773.

Article  PubMed  Google Scholar 

Jing X-L, Chen S-W. Aurora kinase inhibitors: a patent review (2014–2020). Expert Opin Ther Pat. 2021;31(7):625–43.

Article  PubMed  CAS  Google Scholar 

Xu S, Yu Y, Rong J, Hu D, Zhang L, Fu S, Yang H, Fan J, Yang L, Wu J. Expression of BRCA1 and ERCC1 as predictive clinical outcome after radiochemotherapy in patients with locoregionally moderate-advanced nasopharyngeal carcinoma. Oncotarget. 2017;8(19):31355.

Article  PubMed  PubMed Central  Google Scholar 

Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res. 2011;17(24):7614–24.

Article  PubMed  CAS  Google Scholar 

Xu S, Tang YY, Yu YX, Yun Q, Yang JP, Zhang H, Peng Q, Sun X, Yang LL, Fu S. Novel composite drug delivery system as a novel radio sensitizer for the local treatment of cervical carcinoma. Drug Delivery. 2017;24(1):1139–47.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Xu S, Du X, Feng G, Zhang Y, Li J, Lin B, Yang L, Fu S, Wu J. Efficient inhibition of cervical cancer by dual drugs loaded in biodegradable thermosensitive hydrogel composites. Oncotarget. 2018;9(1):282.

Article  PubMed  Google Scholar 

Xu S, Sak A, Erol YB. Network meta-analysis of first-line systemic treatment for patients with metastatic colorectal cancer. Cancer Control. 2021;28:10732748211033496.

Article  PubMed  PubMed Central  Google Scholar 

Siegel RL, Miller KD, Jemal A. Cancer statistics. Cancer J Clin. 2018. https://doi.org/10.3322/caac.21442.

Article  Google Scholar 

Wei X-L, Wang D-S, Xi S-Y, Wu W-J, Chen D-L, Zeng Z-L, Wang R-Y, Huang Y-X, Jin Y, Wang F. Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. World J Gastroenterol: WJG. 2014;20(48):18404.

Article  PubMed  PubMed Central  Google Scholar 

Mamo A, Cavallone L, Tuzmen S, Chabot C, Ferrario C, Hassan S, Edgren H, Kallioniemi O, Aleynikova O, Przybytkowski E. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene. 2012;31(16):2090–100.

Article  PubMed  CAS  Google Scholar 

Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov. 2013;3(1):35–43.

Article  PubMed  CAS  Google Scholar 

Chou A, Toon CW, Clarkson A, Sioson L, Houang M, Watson N, DeSilva K, Gill AJ. Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Hum Pathol. 2014;45(8):1697–703.

Article  PubMed  CAS  Google Scholar 

Lee SY, Kim D-W, Lee HS, Ihn MH, Oh H-K, Park DJ, Kim H-H, Kang S-B. Loss of AT-rich interactive domain 1A expression in gastrointestinal malignancies. Oncology. 2015;88(4):234–40.

Article  PubMed  CAS  Google Scholar 

Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat. 2012;33(1):100–3.

Article  PubMed  CAS  Google Scholar 

Kim K-J, Jung HY, Oh M-H, Cho H, Lee J-H, Lee HJ, Jang S-H, Lee MS. Loss of ARID1A expression in gastric cancer: correlation with mismatch repair deficiency and clinicopathologic features. J Gastric Cancer. 2015;15(3):201–8.

Article  PubMed  PubMed Central  Google Scholar 

Inada R, Sekine S, Taniguchi H, Tsuda H, Katai H, Fujiwara T, Kushima R. ARID1A expression in gastric adenocarcinoma: clinicopathological significance and correlation with DNA mismatch repair status. World J Gastroenterol. 2015;21(7):2159.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43(12):1219–23.

Article  PubMed  CAS  Google Scholar 

Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, Badham N, Rafiq R, Brough R, Gulati A. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat Commun. 2016;7(1):13837.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mountzios G, Terpos E, Dimopoulos M-A. Aurora kinases as targets for cancer therapy. Cancer Treat Rev. 2008;34(2):175–82.